Point-of-Care Testing: An Introduction
暂无分享,去创建一个
[1] W. Maughan,et al. Clinical outcomes of point-of-care testing in the interventional radiology and invasive cardiology setting. , 2000, Clinical chemistry.
[2] D. Nathan,et al. Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: implications for managing point of care testing. , 1994, The American journal of medicine.
[3] J. Boldt,et al. Point-of-care (POC) measurement of coagulation after cardiac surgery , 1998, Intensive Care Medicine.
[4] G. Gravlee,et al. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation. , 1990, The Journal of thoracic and cardiovascular surgery.
[5] B. Luce,et al. The Economic and Clinical Efficiency of Point-of-Care Testing for Critically Ill Patients: A Decision-Analysis Model , 1998, American journal of medical quality : the official journal of the American College of Medical Quality.
[6] D. Jobes,et al. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. , 1995, The Journal of thoracic and cardiovascular surgery.
[7] D. Christensen,et al. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. , 2003, Journal of the American Pharmaceutical Association.
[8] C. Hepler,et al. Opportunities and responsibilities in pharmaceutical care. , 1990, American journal of hospital pharmacy.
[9] J. Nosanchuk,et al. Cost analysis of point-of-care laboratory testing in a community hospital. , 1995, American journal of clinical pathology.
[10] G J Kost,et al. Preventing medical errors in point-of-care testing: security, validation, safeguards, and connectivity.. , 2001, Archives of pathology & laboratory medicine.
[11] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[12] P. St-Louis. Status of point-of-care testing: promise, realities, and possibilities. , 2000, Clinical biochemistry.
[13] R. Grieve,et al. Near patient testing in diabetes clinics: appraising the costs and outcomes. , 1999, Health technology assessment.
[14] L. Goodnough,et al. Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. , 1997, Clinical chemistry.
[15] G. Raskob,et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. , 1997, Archives of internal medicine.
[16] L. Kohn,et al. To Err Is Human : Building a Safer Health System , 2007 .
[17] G. Kost. Guidelines for point-of-care testing. Improving patient outcomes. , 1995, American journal of clinical pathology.
[18] J W Winkelman,et al. The fiscal consequences of central vs distributed testing of glucose. , 1994, Clinical chemistry.
[19] D. Greenblatt,et al. Influence of serum digoxin concentration measurements on frequency of digitoxicity , 1974, Clinical pharmacology and therapeutics.
[20] W. Rosenthal. Establishing a pharmacy-based laboratory service. , 2000, Journal of the American Pharmaceutical Association.
[21] M. Rupp,et al. Developing and marketing a community pharmacy-based asthma management program. , 1997, Journal of the American Pharmaceutical Association.
[22] R H Christenson,et al. Cardiac markers: point of care testing. , 1999, Clinica chimica acta; international journal of clinical chemistry.
[23] R. Becker,et al. Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: a coronary care unit experience. , 1994, American heart journal.
[24] J. Mckenney,et al. Pharmaceutical care services and results in project ImPACT: hyperlipidemia. , 2000, Journal of the American Pharmaceutical Association.